(fifthQuint)Avonex 15 Year Long Term Follow-up Study.

 The primary objective of this study is to determine the impact of early versus delayed initiation of treatment on the long-term physical status of patients with relapsing forms of MS measured by the self-reported EDSS.

 Primary endpoints for this study were as follows: 1.

 Changes in EDSS score from baseline for original Avonex(R) pivotal trial 2.

 Percentage of patients with EDSS scores less than or equal to 4 3.

 Percentage of patients with EDSS scores less than or equal to 6 4.

 Percentage of patients with EDSS scores less than or equal to 7 Secondary endpoints were: 1.

 Percentage of patients alive 2.

 Percentage of patients living independently 3.

 SF 36 Quality of Life status 4.

 Self-reported VAS of independence with self-care.

 Avonex 15 Year Long Term Follow-up Study@highlight

The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM IFN-1a treatment on long-term disability and Quality of Life outcomes in patients who completed 2 years in a previous Multiple Sclerosis Collaborative Research Group (MSCRG) study.

